Israel Englander Aeterna Zentaris Inc. Transaction History

Millennium Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.17 - $0.37 $17,457 - $37,995	102,690 New	102,690 $20,000
Q1 2022 May 16, 2022	SELL	$0.33 - $0.42 $18,265 - $23,247	-55,351 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$0.36 - $0.77 $1,117 - $2,390	3,105 Added 5.94%	55,351 $20,000
Q3 2021 Nov 15, 2021	BUY	$0.59 - $0.88 $411 - $613	697 Added 1.35%	52,246 $39,000
Q2 2021 Aug 16, 2021	SELL	$0.83 - $1.14 $135,109 - $185,571	-162,782 Reduced 75.95%	51,549 $45,000
Q1 2021 May 17, 2021	BUY	$0.51 - $3.34 $109,308 - $715,865	214,331 New	214,331 $244,000
Q3 2018 Nov 14, 2018	SELL	$1.6 - $2.03 $16,884 - $21,422	-10,553 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$1.19 - $2.62 $12,558 - $27,648	10,553 New	10,553 $21,000

Ticker AEZS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,855,880
Market Cap $19.4M
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.